1. OS by OR for the Sorafenib plus HAIC Group
Sup. Fig 1
Median OS (months) (95% CI)
ーResponse: 23.0 ( )
ーNon response: ( )
　 HR(95%CI): 0.28 ( )
Mantel-Byar Test: p<0.0001
Probability
Number of patients at risk:
Time from randomization (months)
Response 37 36 29 19 15 8 3 1
Non response 45 27 16 7

2. Probability Response 27 20 16 10 6 3 1 Non response 46 29 18 4
Sup. Fig 2A
Landmark Analyses for OS by OR in the Sorafenib plus HAIC Group
(Landmark KM curve as function of tumor response at 4 months)
Median OS (months) (95% CI)
ーResponse: 14.1 ( )
ーNon response: ( )
　 HR(95%CI): 0.74 ( )
Log rank Test: p=0.2752
Probability
Number of patients at risk:
Time from 4 months after randomization (months)
Response 27 20 16 10 6 3 1
Non response 46 29 18 4

3. Probability Response 31 24 16 12 7 3 1 Non response 32 21 10 6
Sup. Fig 2B
Landmark Analyses for OS by OR in the Sorafenib Alone Group
(Landmark KM curve as function of tumor response at 6 months)
Median OS (months) (95% CI)
ーResponse: 17.0 ( )
ーNon response: ( )
　 HR(95%CI): 0.54 ( )
Log rank Test: p=0.0439
Probability
Number of patients at risk:
Time from 6 months after randomization (months)
Response 31 24 16 12 7 3 1
Non response 32 21 10 6

4. Probability Response 28 24 16 10 5 3 1 Non response 29 17 6
Sup. Fig 2C
Landmark Analyses for OS by OR in the Sorafenib Alone Group
(Landmark KM curve as function of tumor response at 8 months)
Median OS (months) (95% CI)
ーResponse: 19.3 (13.2-NR)
ーNon response: ( )
　 HR(95%CI): 0.36 ( )
Log rank Test: p<0.0001
Probability
Time from 8 months after randomization (months)
Number of patients at risk:
Response 28 24 16 10 5 3 1
Non response 29 17 6

5. Multivariable Analysis
Sup. Table1
Univariable and Multivariable Analysis of Factors Associated with OS (Sorafenib plus HAIC Group)
Univariable Analysis
Multivariable Analysis
Parameter
HR [95% CI]
p Value
Response (CR+PR vs SD+PD)
0.36
[0.21-
0.64]
0.0004
0.32
[0.18-
0.59]
0.0003
Age (>65 vs <65)
1.63
[0.97-
2.73]
0.0651
1.70
[0.94-
3.08]
0.0788
Sex (Male vs Female)
0.43
0.89]
0.0231
0.67
[0.28-
1.61]
0.3730
PS (1 vs 0)
2.66
[1.31-
5.37]
0.0066
1.54
[0.65-
3.69]
0.3284
Vp(Vp1-4 vs Vp0)
0.87
[0.53-
1.42]
0.5777
Extrahepatic spread (yes vs no)
0.94
1.66]
0.8213
HBV (yes vs no)
[0.50-
1.52]
0.6276
HCV (yes vs no)
1.30
[0.79-
2.13]
0.2981
Albumin (>3.6 mg/dl vs <3.6 mg/dl)
0.55
[0.33-
0.90]
0.0169
0.98
[0.48-
1.98]
0.9446
Bilirubin(>0.8 mg/dl vs <0.8 mg/dl)
1.22
[0.74-
2.00]
0.4348
ALBI grade (Grade2 vs Grade1)
1.95
[1.11-
3.45]
0.0208
1.66
[0.78-
3.53]
0.1855
AFP(>400 ng/ml vs <400 ng/ml)
2.06
[1.24-
0.0056
2.46
[1.33-
4.55]
0.0043
PIVKA-II (>2050 mAU/ml vs <2050 mAU/ml)
1.11
[0.67-
1.84]
0.6824